Gregory Batcheller has been the chairman of biopharma Xintela since 2011. During this time he has seen the company reach several milestones and now has two ongoing clinical phase I/IIa studies with XSTEM. Batcheller visited BioStock's studio to tell us more about the company's journey and business development.
See the interview at biostock.se:
https://www.biostock.se/en/2023/03/xintelas-chairman-about-the-companys-journey/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/